ENDPOINTS

Novo makes oral obesity drug partnership with Lexicon worth up to $1B

Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday announced a licensing deal with a Texas biotech to get access to its oral small molecule drug. Under the deal, Lexicon Pharmaceuticals will ...

Mar 28, 2025 - 12:33
 0
Novo makes oral obesity drug partnership with Lexicon worth up to $1B
Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday announced a licensing deal with a Texas biotech to get access to its oral small molecule drug. Under the deal, Lexicon Pharmaceuticals will ...
Read More

Tags:

Previous Article

March 2025 Partial Solar Eclipse: Where and How to Watch

Next Article

Slashing Programs That Help People with Disabilities Is a Nod to Eugenics

Related Posts

Walgreens to go private in $10B deal

Walgreens to go private in $10B deal

Mar 6, 2025  0

Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets

Akeso shares new data for bispecific in cervical cancer...

Mar 21, 2025  0

FDA critiques 'misleading' Taiho promotion of bile duct cancer drug

FDA critiques 'misleading' Taiho promotion of bile duct...

Mar 26, 2025  0